Skip to Content

Reolysin Approval Status

FDA Approved: No
Brand name: Reolysin
Generic name: pelareorep
Company: Oncolytics Biotech Inc.
Treatment for: Ovarian Cancer, Pancreatic Cancer, Malignant Glioma

Reolysin (pelareorep) is a proprietary formulation of the human reovirus (Respiratory Enteric Orphan Virus) in development for the treatment of various cancers and cell proliferative disorders.

Development Status and FDA Approval Process for Reolysin

DateArticle
Apr 17, 2015Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the FDA for Malignant Gliomas
Feb 17, 2015Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from FDA for Reolysin for Pancreatic Cancer
Feb 11, 2015Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from FDA for Reolysin for Ovarian Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide